Your browser doesn't support javascript.
loading
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin.
Goodarzi, Navid; Barazesh Morgani, Ahmadreza; Abrahamsson, Bertil; Cristofoletti, Rodrigo; Groot, D W; Langguth, Peter; Mehta, Mehul U; Polli, James E; Shah, Vinod P; Dressman, Jennifer B.
Afiliação
  • Goodarzi N; Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Barazesh Morgani A; Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Abrahamsson B; Pharmaceutical Development, AstraZeneca R&D, Mölndal, Sweden.
  • Cristofoletti R; Brazilian Health Surveillance Agency (Anvisa), Division of Therapeutic Equivalence, Brasilia, Brazil.
  • Groot DW; RIVM - National Institute for Public Health and the Environment, Bilthoven, Utrecht, The Netherlands.
  • Langguth P; Institute of Pharmacy, Johannes Gutenberg University, Mainz, Germany.
  • Mehta MU; Food and Drug Administration, Center for Drug Evaluation, Silver Spring, Maryland 20993.
  • Polli JE; Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201.
  • Shah VP; International Pharmaceutical Federation FIP, The Hague, The Netherlands.
  • Dressman JB; Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany. Electronic address: dressman@em.uni-frankfurt.de.
J Pharm Sci ; 105(4): 1362-9, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26952879

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Antivirais / Ribavirina Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Pharm Sci Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Antivirais / Ribavirina Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Pharm Sci Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Irã